UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 539

Sortiert nach

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

The lancet oncology, 2020-06, Vol.21 (6), p.808-820

2020

Link zum Volltext

Verfügbarkeit prüfen

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Annals of oncology, 2016-12, Vol.27 (12), p.2196-2203

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors

Annals of oncology, 2019-07, Vol.30 (7), p.1134-1142

2019

Link zum Volltext

Verfügbarkeit prüfen

Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance)

Annals of oncology, 2021-10, Vol.32 (10), p.1267-1275

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer

Annals of oncology, 2015-04, Vol.26 (4), p.804-811

2015

Link zum Volltext

Verfügbarkeit prüfen

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors

Annals of oncology, 2015-01, Vol.26 (1), p.58-64

2015

Link zum Volltext

Verfügbarkeit prüfen

Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)

Annals of oncology, 2020-01, Vol.31 (1), p.79-87

2020

Link zum Volltext

Verfügbarkeit prüfen

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors

Annals of oncology, 2020-05, Vol.31 (5), p.626-633

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors

Annals of oncology, 2014-07, Vol.25 (7), p.1416-1421

2014

Link zum Volltext

Verfügbarkeit prüfen

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors

Investigational new drugs, 2016-12, Vol.34 (6), p.740-749

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer

Annals of oncology, 2018-06, Vol.29, p.v123-v123

2018

Link zum Volltext

Verfügbarkeit prüfen

Consideration of an association between performance status and ramucirumab efficacy

Annals of oncology, 2017-04, Vol.28 (4), p.902-903

2017

Link zum Volltext

Verfügbarkeit prüfen

Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

Cancer, 2003-06, Vol.97 (12), p.2972-2977

2003

Link zum Volltext

Verfügbarkeit prüfen

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Annals of oncology, 2019-12, Vol.30 (12), p.2016-2016

2019

Link zum Volltext

Verfügbarkeit prüfen

A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy

Annals of oncology, 2018-10, Vol.29, p.viii265-viii265

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy - Trial in progress

Annals of oncology, 2018-06, Vol.29, p.v25-v26

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer

Investigational new drugs, 2018-12, Vol.36 (6), p.1037-1043

2018

Link zum Volltext

Verfügbarkeit prüfen

Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy

Annals of oncology, 2016-12, Vol.27 (12), p.2216-2224

2016

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies

Annals of oncology, 2018-10, Vol.29, p.viii222-viii222

2018

Link zum Volltext

Verfügbarkeit prüfen

Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)

Annals of oncology, 2019-07, Vol.30, p.iv122-iv122

2019

Link zum Volltext

Verfügbarkeit prüfen

A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer

Gynecologic oncology, 2017-11, Vol.147 (2), p.276-282

2017

Link zum Volltext

Verfügbarkeit prüfen

Safety and Effectiveness of Bevacizumab Treatment for Metastatic Colorectal Cancer: Final Results from the Avastin® Registry – Investigation of Effectiveness and Safety (ARIES) Observational Cohort Study

Clinical oncology (Royal College of Radiologists (Great Britain)), 2014-06, Vol.26 (6), p.323-332

2014

Link zum Volltext

Verfügbarkeit prüfen

Results of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer

Annals of oncology, 2018-10, Vol.29, p.viii189-viii190

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase I trial of vorolanib (X-82t vascular endothelial growth factor receptor (VEGFR) inhibitor, in patients (pts) with advanced solid tumors

Annals of oncology, 2018-10, Vol.29, p.viii659-viii660

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 539

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(487)
Mit Volltextzugriff
(509)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(167)
Life Sciences & Biomedicine
(145)
Humans
(99)
Oncology
(81)
Female
(80)
Male
(69)
Middle Aged
(57)
Biological And Medical Sciences
(53)
Adult
(52)
Aged
(52)
Animals
(29)
Medical Sciences
(29)
Tumors
(28)
Environmental Sciences & Ecology
(26)
Aged, 80 And Over
(25)
Fundamental And Applied Biological Sciences. Psychology
(25)
Neoplasms - Drug Therapy
(25)
Social Sciences
(25)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(24)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(21)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors

Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance)

Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors

Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors

Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer

Consideration of an association between performance status and ramucirumab efficacy

Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy

A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy - Trial in progress

Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer

Corrigendum to ‘Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)’: Annals of Oncology, Volume 31, Issue 1, 2020, Pages 79–87

Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy

Safety and efficacy of a DKK1 inhibitor (DKN-01) in combination with pembrolizumab (P) in patients (Pts) with advanced gastroesophageal (GE) malignancies

Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)

A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer

Safety and Effectiveness of Bevacizumab Treatment for Metastatic Colorectal Cancer: Final Results from the Avastin® Registry – Investigation of Effectiveness and Safety (ARIES) Observational Cohort Study

Results of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer

A phase I trial of vorolanib (X-82t vascular endothelial growth factor receptor (VEGFR) inhibitor, in patients (pts) with advanced solid tumors

Suchergebnisse filtern